![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | Completed |
Unique ID issued by UMIN | UMIN000003763 |
Receipt No. | R000004213 |
Scientific Title | Effects of entecavir plus branched-chain amino acids versus entecavir alone in nucleoside-naïve Japanese adult patients with chronic hepatitis B virus infection : An open-label randomized controlled trial. |
Date of disclosure of the study information | 2010/06/16 |
Last modified on | 2013/06/27 |
Basic information | ||
Public title | Effects of entecavir plus branched-chain amino acids versus entecavir alone in nucleoside-naïve Japanese adult patients with chronic hepatitis B virus infection : An open-label randomized controlled trial. | |
Acronym | Trial M | |
Scientific Title | Effects of entecavir plus branched-chain amino acids versus entecavir alone in nucleoside-naïve Japanese adult patients with chronic hepatitis B virus infection : An open-label randomized controlled trial. | |
Scientific Title:Acronym | Trial M | |
Region |
|
Condition | ||
Condition | Chronic hepatitis B | |
Classification by specialty |
|
|
Classification by malignancy | Others | |
Genomic information | NO |
Objectives | |
Narrative objectives1 | efficacy of entecavir plus branched-chain amino acids |
Basic objectives2 | Efficacy |
Basic objectives -Others | |
Trial characteristics_1 | Confirmatory |
Trial characteristics_2 | |
Developmental phase | Phase III |
Assessment | |
Primary outcomes | the change from baseline in mean serum HBV-DNA level at week 12 |
Key secondary outcomes | the change from baseline in mean serum HBV-DNA level at week 4 and 8
the change from baseline in mean serum albumin level, ALT level, total bilirubin level and total cholesterol level at week 12 Safety (moniterd clinical and laboratory evaluation) |
Base | |
Study type | Interventional |
Study design | |
Basic design | Parallel |
Randomization | Randomized |
Randomization unit | Individual |
Blinding | Open -no one is blinded |
Control | Active |
Stratification | NO |
Dynamic allocation | NO |
Institution consideration | Institution is not considered as adjustment factor. |
Blocking | NO |
Concealment | Central registration |
Intervention | ||
No. of arms | 2 | |
Purpose of intervention | Treatment | |
Type of intervention |
|
|
Interventions/Control_1 | entecavir plus branched-chain amino acids | |
Interventions/Control_2 | entecavir alone2 | |
Interventions/Control_3 | ||
Interventions/Control_4 | ||
Interventions/Control_5 | ||
Interventions/Control_6 | ||
Interventions/Control_7 | ||
Interventions/Control_8 | ||
Interventions/Control_9 | ||
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Male and Female | |||
Key inclusion criteria | 1) nucleoside-naïve Japanese adult patients with chronic hepatitis B virus infection
2)albumin level 4.0 g/dl or less |
|||
Key exclusion criteria | 1) a history of allergy induced by nucleoside analog or exposure to nucleoside analogs
2) had a history of oral BCAA supplementation for 6 months or longer 3) Pregnant or lactating women and women who may be pregnant 4) had major complication of liver cirrhosis, such as HCC, variceal bleeding, hepatic encephalopathy or ascites requiring diuretics, 5) had other nonhepatic major diseases 6) Patients with other liver disease (e.g., hepatitis C virus, alchol) 7) Judged by investigator not to be appropriate for inclusion in this study |
|||
Target sample size | 40 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | graduate school of biomedical science, Hiroshima university. | ||||||
Division name | Department and medicine and molecular science | ||||||
Zip code | |||||||
Address | 1-2-3 kasumi, minami-ku, Hiroshima 734-8551 | ||||||
TEL | 082-257-5190 | ||||||
Public contact | |||||||
Name of contact person |
|
||||||
Organization | graduate school of biomedical science, Hiroshima university | ||||||
Division name | Department and medicine and molecular science | ||||||
Zip code | |||||||
Address | 1-2-3 kasumi, minami-ku, Hiroshima 734-8551 | ||||||
TEL | 082-257-5190 | ||||||
Homepage URL | |||||||
Sponsor | |
Institute | Hiroshima liver study group |
Institute | |
Department |
Funding Source | |
Organization | none |
Organization | |
Division | |
Category of Funding Organization | Self funding |
Nationality of Funding Organization |
Other related organizations | |
Co-sponsor | |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | |
Address | |
Tel | |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions | 川上消化器内科クリニック、広島赤十字原爆病院、JA尾道総合病院、県立広島病院、呉医療センター、安佐市民病院、中国労災病院、広島鉄道病院、三次中央病院 |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | |
Publication of results | Unpublished |
Result | |
URL related to results and publications | |
Number of participants that the trial has enrolled | |
Results | |
Results date posted | |
Results Delayed | |
Results Delay Reason | |
Date of the first journal publication of results | |
Baseline Characteristics | |
Participant flow | |
Adverse events | |
Outcome measures | |
Plan to share IPD | |
IPD sharing Plan description |
Progress | |||||||
Recruitment status | Completed | ||||||
Date of protocol fixation |
|
||||||
Date of IRB | |||||||
Anticipated trial start date |
|
||||||
Last follow-up date |
|
||||||
Date of closure to data entry | |||||||
Date trial data considered complete | |||||||
Date analysis concluded |
Other | |
Other related information |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004213 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |